الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 155 |  |  |
| | | from | 155 | | |
Abstract
Approximately, 130–150 million people are infected with HCV; each year, besides an estimated 399 000 people die from complications of HCV including cirrhosis, malignant neoplastic disease (hepatocellular carcinoma) and liver failure. Unluckily, many people with HCV only know about their infection when they experience symptoms of cirrhosis or liver cancer.
The association between hepatitis C virus (HCV) infection and diabetes has been widely postulated. Prospective studies have demonstrated a higher risk of developing type 2 diabetes mellitus (T2DM) and insulin resistance in the HCV population.
Therefore, it is presumed that effective HCV management would result in improved glycemic control in diabetic patients. Recently, a growing body of evidence has shown a promising role of effective HCV eradication on glycemic control of diabetic patients; previous reports showed that the change in HbA1c was greater in those who achieved SVR with DAAs than in those who sustained treatment failure.
Aim of this study was to evaluate effect of treatment of hepatitis C virus by Direct Acting Antiviral Drugs (DAAS) on Glycemic Control of Diabetic HCV Infected Patients
This study was conducted in viral hepatitis treatment center at Aswan Fever.
Hospital and Ain Shams University Hospital in the period between May 2019 to December 2019. At the beginning of the present prospective study, we included 96 diabetic patients with chronic HCV infection, however, only 80 patients were included in the final analysis; while the remaining of the study group were excluded due to loss of follow-up and uncompliance of treatment.
Patients received Direct Acting Antiviral regimens according to criteria matched in the National Committee for Control of Viral Hepatitis C treatment protocols that of the total studied subjects, 77 subjects received Sofosbuvir and Daclatasvir, and 3 subjects received Sofosbuvir, Daclatasvir and Ribavirin.
HbA1C level, Fasting blood sugar level, fasting blood insulin level and HOMA- IR are measured at base line then 12 weeks after end of treatment with DAAS considered responder when patients remain non-viremic as identified by negative HCV RNA serum PCR at the end of the treatment
The present study showed a significant impact of HCV eradication with DAAS on the glycemic control of diabetic patients with chronic HCV infection , not only improvement in HbA1c level and fasting blood suger but also decrease in insulin resistance.